Macroscopic tumor volume of malignant glioma determined by contrast-enhanced magnetic resonance imaging with and without magnetization transfer contrast

A comparison study of (11)C-methionine and (18)F-fluorodeoxyglucose positron emission tomography-computed tomography scans in evaluation of patients with recurrent brain tumors

Introduction:

¹¹C-methonine ([¹¹C]-MET) positron emission tomography-computed tomography (PET-CT) is a well-established technique for evaluation of tumor for diagnosis and treatment planning in neurooncology. [¹¹C]-MET reflects amino acid transport and has been shown to be more sensitive than magnetic resonance imaging (MRI) in stereotactic biopsy planning. This study compared fluorodeoxyglucose (FDG) PET-CT and MET PET-CT in the detection of various brain tumors.

Materials and Methods:

Sixty-four subjects of brain tumor treated by surgery, chemotherapy, and/or radiotherapy were subjected to [¹⁸F]-FDG, [¹¹C]-MET, and MRI scan. The lesion was analyzed semiquantitatively using tumor to normal contralateral ratio. The diagnosis was confirmed by surgery, stereotactic biopsy, clinical follow-up, MRI, or CT scans.

Results:

Tumor recurrence was found in 5 out of 22 patients on [F-18] FDG scan while [¹¹C]-MET was able to detect recurrence in 18 out of 22 patients in low-grade gliomas. Two of these patients were false positive for the presence of recurrence of tumor and later found to be harboring necrosis. Among oligodendroglioma, medulloblastoma and high-grade glioma out of 42 patients 39 were found to be concordant MET and FDG scans. On semiquantitative analysis, mean T/NT ratio was found to be 2.96 ± 0.94 for lesions positive for recurrence of tumors and 1.18 ± 0.74 for lesions negative for recurrence of tumor on [¹¹C]-MET scan. While the ratio for FDG scan on semiquantitative analysis was found to be 2.05 ± 1.04 for lesions positive for recurrence of tumors and 0.52 ± 0.15 for lesions negative for recurrence of tumors.

Conclusion:

The study highlight that [¹¹C]-MET is superior to [¹⁸F]-FDG PET scans to detect recurrence in low-grade glioma. A cut-off value of target to nontarget value of 1.47 is a useful parameter to distinguish benign from malignant lesion on an [¹¹C]-MET Scan. Both [¹⁸F]-FDG and [¹¹C]-MET scans were found to be useful in high-grade astrocytoma, oligodendroglioma, and medulloblastoma.

Evaluation of human brain tumor heterogeneity using multiple T1-based MRI signal weighting approaches

Vascular-space-occupancy (VASO) MRI without contrast injection was explored for imaging cerebral blood volume (CBV) and tissue heterogeneity in gliomas (n = 10). VASO contrast complemented contrast-enhanced T(1)-weighted (GAD-T(1)w), FLAIR and T(1)w magnetization-prepared-rapid-gradient-echo (MPRAGE) images. High-grade gliomas showed a VASO-outlined hyperintense zone corresponding to long-T(1) regions in MPRAGE and to nonenhancing regions in GAD-T(1)w images. FLAIR, MPRAGE, and VASO data were used to segment tumors into multiple zones of different T(1). After removal of known resection areas using pre- and postsurgical MRI, the volume of overlap between the hyperintense VASO-zone and the long-T(1) MPRAGE zone correlated with that of GAD-T(1)w enhancement (R(2) = 0.99) and tumor grade. Based on these correlations, this remaining long T(1) overlap area was tentatively assigned to necrosis. In one promising case the collective T(1)-weighted approach accurately identified a low-grade glioma despite the presence of contrast enhancement in GAD-T(1)w images consequential to chemoradiation-associated treatment effect. The results suggest that this collective T(1)-weighted approach may provide useful information for regional assessment of heterogeneous tumors and for guiding treatment-related decisions in patients with gliomas.

Early radiotherapy dose response and lack of hypersensitivity effect in normal brain tissue: a sequential dynamic susceptibility imaging study of cerebral perfusion

AIMS

To determine if magnetic resonance perfusion markers can be used as an analytical marker of subclinical normal brain injury after radiotherapy, by looking for a dose-effect relationship.

MATERIALS AND METHODS

Four patients undergoing conformal radiotherapy to 54Gy in 30 fractions for low-grade gliomas were imaged with conventional T(2)-weighted and fluid attenuated inversion recovery imaging as well as dynamic contrast susceptibility perfusion imaging. Forty regions of interest were determined from the periventricular white matter. All conventional sequences were examined for evidence of radiation-induced changes. Patients were imaged before radiotherapy, after one fraction, at the end of treatment and then at 1 and 3 months from the end of radiotherapy. For each region the relative cerebral blood volume (rCBV), relative cerebral blood flow (rCBF) and mean transit time (MTT) expressed as a ratio of the baseline value, and radiotherapy dose were determined.

RESULTS

Of the 40 regions, seven occurred within the gross tumour volume and a further four occurred in regions later infiltrated by tumour, and were thus excluded. Regions within the 80% isodose showed a reduction in rCBV and rCBF over the 3 month period. There was no significant alteration in rCBV or rCBF in regions outside the 60% isodose (i.e. <32Gy). MTT did not alter in any region. There seemed to be a threshold effect at 132 days from the end of radiotherapy of 47% (standard error of the mean 11.5, about 25.4Gy) for rCBV and 59% (standard error of the mean 14.2, about 31.9Gy) for rCBF.

CONCLUSIONS

There was a dose-related reduction in rCBV and rCBF in normal brain after radiotherapy at higher dose levels. Although this study used a limited number of patients, it suggests that magnetic resonance perfusion imaging seems to act as a marker of subclinical response of normal brain and that there is an absence of an early hypersensitivity effect with small doses per fraction. Further studies are required with larger groups of patients to show that these results are statistically robust.

Optimizing localization accuracy in head and neck, and brain radiotherapy

The purpose of this study was to investigate the impact on localization of utilizing contrast-enhanced CT scans and the formal input of a radiologist in the planning process. 25 head and neck/brain patients had pre- and post-contrast CT scans in the treatment position. Radiotherapy treatment was planned on the unenhanced CT images as per standard practice. Retrospectively, their scans (unenhanced and enhanced) were re-contoured by two oncologists and a radiologist. These new contours were compared with the original unenhanced treatment contours and differences in contour volume, geographical isocentre position and tolerance coverage of the associated planning target volumes (PTVs) were evaluated using the original plans. The use of contrast enhanced CT data during localization by the oncologist shows little change in gross tumour volumes (GTVs) or PTVs, geographical position or tolerance coverage for the targets in the brain studied here. Larger changes in mean volume are seen for the head and neck cases alone. Changes are greater and statistically significant (p < 0.05, Wilcoxon signed rank test) for localization by the radiologist. Furthermore, when comparing the original PTV marked by the oncologist with a new PTV re-contoured by the oncologist, but based on a GTV marked-up by the radiologist, again statistically significant (p < 0.01) changes in percentage volume are noted. Intraoperator precision is good, percentage volume differences being of the order 3-6%. PTVs also show improved standard deviations compared with GTVs. Geographic shifts are generally within our departmental tolerance levels for daily patient setup. Comparing precision of unenhanced data with enhanced, mean percentage volume changes are smaller, but not statistically significant. The use of enhanced scan data for localization has little effect on size, geographical position or tolerance coverage of PTVs marked up by the oncologists in this study. However, more important is the input from a radiologist. Statistically significant differences due to mark-up on enhanced scans by the radiologist are shown. Furthermore, significant differences are also seen between PTVs based on oncologist-generated GTVs, and those based on radiologist-generated GTVs.

Tissue signature characterisation of diffusion tensor abnormalities in cerebral gliomas

The inherent invasiveness of malignant cells is a major determinant of the poor prognosis of cerebral gliomas. Diffusion tensor MRI (DTI) can identify white matter abnormalities in gliomas that are not seen on conventional imaging. By breaking down DTI into its isotropic (p) and anisotropic (q) components, we can determine tissue diffusion "signatures". In this study we have characterised these abnormalities in peritumoural white matter tracts. Thirty-five patients with cerebral gliomas and seven normal volunteers were imaged with DTI and T2-weighted sequences at 3 T. Displaced, infiltrated and disrupted white matter tracts were identified using fractional anisotropy (FA) maps and directionally encoded colour maps and characterised using tissue signatures. The diffusion tissue signatures were normal in ROIs where the white matter was displaced. Infiltrated white matter was characterised by an increase in the isotropic component of the tensor (p) and a less marked reduction of the anisotropic component (q). In disrupted white matter tracts, there was a marked reduction in q and increase in p. The direction of water diffusion was grossly abnormal in these cases. Diffusion tissue signatures may be a useful method of assessing occult white matter infiltration.

MRI of the tumor microenvironment

The microenvironment within tumors is significantly different from that in normal tissues. A major difference is seen in the chaotic vasculature of tumors, which results in unbalanced blood supply and significant perfusion heterogeneities. As a consequence, many regions within tumors are transiently or chronically hypoxic. This exacerbates tumor cells' natural tendency to overproduce acids, resulting in very acidic pH values. The hypoxia and acidity of tumors have important consequences for antitumor therapy and can contribute to the progression of tumors to a more aggressive metastatic phenotype. Over the past decade, techniques have emerged that allow the interrogation of the tumor microenvironment with high resolution and molecularly specific probes. Techniques are available to interrogate perfusion, vascular distribution, pH, and pO(2) nondestructively in living tissues with relatively high precision. Studies employing these methods have provided new insights into the causes and consequences of the hostile tumor microenvironment. Furthermore, it is quite exciting that there are emerging techniques that generate tumor image contrast via ill-defined mechanisms. Elucidation of these mechanisms will yield further insights into the tumor microenvironment. This review attempts to identify techniques and their application to tumor biology, with an emphasis on nuclear magnetic resonance (NMR) approaches. Examples are also discussed using electron MR, optical, and radionuclear imaging techniques.